C-Path Partners with FARA to Fortify RDCA-DAP and Further Accelerate Drug Development with new Friedreich’s Ataxia Data

Critical Path Institute (C-Path), a leader in accelerating drug development for rare diseases, today announced the targeted integration of additional Friedreich’s ataxia (FA) datasets into C-Path’s Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP®) as part of a partnership with Friedreich’s Ataxia Research Alliance (FARA).

“FARA is excited to continue our collaboration with C-Path and foster data sharing from natural history studies and clinical trials to enhance research and analysis aimed at improving outcomes and developing treatments for Friedreich’s ataxia,” said Jennifer Farmer, CEO of FARA. “We believe in making patient contributions of data as meaningful as possible and one way to honor this is by ensuring that such data is available to the research community through a secure and robust platform.”